Literature DB >> 7766945

The international collaborative study of maternal phenylketonuria: status report 1994.

R Koch1, H L Levy, R Matalon, B Rouse, W B Hanley, F Trefz, C Azen, E G Friedman, F de la Cruz, F Güttler.   

Abstract

Neonatal screening for phenylketonuria (PKU) has created a problem as females with PKU are reaching child-bearing age. Surveys have revealed that maternal phenylalanine blood concentrations greater than 1200 mumol/l are associated with fetal microcephaly, congenital heart defects and intrauterine growth retardation. It is estimated that as many as 3000 hyperphenylalaninemic females may be at risk of producing these fetal abnormalities. To examine this problem, the international maternal PKU collaborative study was developed to evaluate the efficacy of a phenylalanine-restricted diet in reducing fetal morbidity. Preliminary findings have indicated that phenylalanine restriction should begin before conception for females with PKU planning a pregnancy. Dietary control should maintain maternal blood phenylalanine levels between 120 and 360 mumol/l and should provide adequate energy, protein, vitamin and mineral intake. Pregnant hyperphenylalaninemic females who achieved metabolic control after conception or by the 10th week of pregnancy had a better offspring outcome than anticipated. The results of 402 pregnancies are reviewed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7766945     DOI: 10.1111/j.1651-2227.1994.tb13468.x

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  2 in total

1.  Phenylalanine hydroxylase gene mutations in the United States: report from the Maternal PKU Collaborative Study.

Authors:  P Guldberg; H L Levy; W B Hanley; R Koch; R Matalon; B M Rouse; F Trefz; F de la Cruz; K F Henriksen; F Güttler
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

2.  Neonatal neurological assessment of offspring in maternal phenylketonuria.

Authors:  S E Waisbren; P Chang; H L Levy; H Shifrin; E Allred; C Azen; F de la Cruz; W Hanley; R Koch; R Matalon; B Rouse
Journal:  J Inherit Metab Dis       Date:  1998-02       Impact factor: 4.982

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.